New hope for AML patients: maintenance chemo combo aims to keep remission going
NCT ID NCT04990102
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a chemotherapy drug called CPX-351 (Vyxeos) as a maintenance treatment for adults with acute myeloid leukemia (AML) who are in remission but cannot have a bone marrow transplant. About 24 participants will receive up to 6 cycles of the drug to see what dose is safest and how well it is tolerated. The goal is to find a way to help keep the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CPX-351 (Vyxeos), a combination of two chemotherapy drugs: daunorubicin and cytarabine
- What this could lead to
- If it works, this could offer a way to keep AML in remission longer for patients who cannot have a bone marrow transplant.
- What could go wrong
- This is an early-phase trial with only 24 people, so it is too small to prove effectiveness. The chemotherapy drugs have known side effects like infection and heart problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.